Skip to main content
OpenTrials
Completed

NCT Number: NCT02054390

Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction

Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Syndrome Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Glucose Metabolism Disorders Heart Diseases Hyperinsulinism Inflammation Insulin Resistance Metabolic Diseases Myocardial Ischemia Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara University School Of Medicine, Department of Cardiology

Ankara, 06230, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • metabolic syndrome
  • elective percutaneous coronary intervention with angiographically successful stent implantation

Exclusion criteria

  • acute coronary events
  • renal failure
  • needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded
  • left main coronary artery disease
  • chronic total occlusion
  • high levels of baseline CKMB or troponin
  • any contraindication of aspirin, clopidogrel or ACEi treatment

Treatment and study plan

Primary outcomes

  1. Periprocedural myocardial injury (MI)

    Time frame: 24 hours after (percutaneous coroary intervention) PCI

    Periprocedural MI was defined as cardiac Troponin I release [5 times ULN] 24 hours after percutaneous coronary intervention

Secondary outcomes

  1. Periprocedural myonecrosis

    Time frame: 24 hours after PCI

    Peri-procedural myonecrosis was defined as troponin I release of >1×ULN 24 hours after the intervention.

Other outcomes

  1. inflammatory marker

    Time frame: 24 hours after PCI

    high sensitive C-reactive protein measurement 24 hours after PCI

Sponsors and collaborators

Lead sponsor

Ankara University

Other

Registry information

Official study title

Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Feb 4, 2014
Registry last updated
Jun 20, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.